IMPORTANCE Exenatide, a glucagon-like peptide 1 agonist used in type 2 diabetes, was recently found to have beneficial effects on motor function in a randomized, placebo-controlled trial in Parkinson disease (PD). Accumulating evidence suggests that impaired brain insulin and protein kinase B (Akt) signaling play a role in PD pathogenesis; however, exploring the extent to which drugs engage with putative mechnisms in vivo remains a challenge.
P revious work 1 has explored the use of extracellular vesicles (EVs) harvested from peripheral blood and enriched for neuronal origin to measure neuropathological changes in vivo over time. Extracellular vesicles (including exosomes) are nanosized membranous particles secreted by virtually all cells, including neurons, 2 that circulate in blood and contain variable cellular cargo representative of their origin, which can be significantly altered depending on the physiologic state of the parent cell. 3 Extracellular vesicles can cross the blood-brain barrier; thus, EVs of neuronal origin can be selectively isolated by targeting neuronal antigens, such as the neuronal cell adhesion molecule and the L1 cell adhesion molecule (L1CAM), embedded in the vesicle membrane. Several studies [4] [5] [6] have used neuronal-derived EVs isolated by L1CAM immunocapture to quantify levels of pathogenic proteins contained within them and have found that they can successfully distinguish between disease states and healthy controls in Alzheimer disease and Parkinson disease (PD). The potential utility of this technique in revealing target engagement and mechanism of action of central nervous sysrem drugs in clinical trials is increasingly being recognized. A variety of novel targets for neuroprotection have been identified and are actively being pursued in clinical trials for neurodegenerative diseases. Among these targets, the identification of metabolic dysfunction in PD is of major interest 7, 8 ; evidence from epidemiologic studies and animal-toxin models of PD suggest that impaired insulin signaling may play a role in the pathogenesis. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In the brain, insulin modulates neuronal cell survival via 2 downstream pathways: the phosphoinositide 3-kinase-protein kinase B (Akt) and mitogenactivated protein kinase (MAPK) pathways ( Figure 1 ). Diminished insulin signaling reduces the activity of Akt, modulating the activity of numerous kinases, including mechanistic target of rapamycin (mTOR), glycogen synthase kinase 3β (GSK-3β), and forkhead box protein O1, which regulate processes involved in PD pathogenesis, 21 such as α-synuclein degradation, 22,23 mitochondrial biogenesis, and modulation of inflammatory and oxidative stress pathways. 24 Insulin signaling relies on the stability of insulin receptor substrate 1 (IRS-1), which acts as the first node in the cascade, and its activity is regulated through a number of serine and tyrosine phosphorylation sites. 25 Although tyrosine IRS-1 phosphorylations are needed for insulin-evoked responses, serine phosphorylations primarily deactivate IRS-1 and attenuate insulin signaling. [26] [27] [28] [29] Prior studies in postmortem tissue from patients with PD, 30, 31 Alzheimer disease, 27-29 and multiple system atrophy 15 have identified elevated IRS-1 phosphorylation at serine positions 616 (IRS-1 p-S616) and 312 (IRS-1 p-S312) as being associated with attenuated insulin signaling, supporting their use as biomarkers of neuronal insulin resistance. Of importance, the reversal and restoration of insulin signaling by exogenous insulin or insulin-sensitizing agents led to improved cell survival and functional improvements.
32-34
Although alternative markers of insulin resistance are available through neuroimaging and cerebrospinal fluid studies, measuring brain insulin-signaling markers in peripheral blood represents a rational, easily accessible, and practical method for assessing time-dependent changes. Previous studies used plasma neuronal-derived EVs to demonstrate decreased tyrosine phosphorylated IRS-1 (IRS-1 p-Tyr) and increased levels of IRS-1 phosphorylated at serine 312 (IRS-1 p-S312) 35 in patients with Alzheimer disease, closely mimicking the pattern observed in autopsy, 36 and have found that therapeutic interventions that target insulin signaling can significantly alter these IRS-1 phosphorylations. 37 Taken together, these findings suggest that IRS-1 and downstream signaling mediators in neuronalderived EVs could be used as biomarkers of brain insulin resistance in neurodegenerative diseases. Glucagon-like peptide 1 (GLP-1) agonists are used for type 2 diabetes treatment and activate similar pathways to insulin to improve glucose homeostasis. 38 The GLP-1 signaling pathways also indirectly promote and restore neuronal insulin signaling, 39,40 reducing serine IRS-1 phosphorylation and monomeric α-synuclein load, preserving dopaminergic neurons, and attenuating cell death in rodent models of multiple systems atrophy and Alzheimer disease.
32,41
A proposed mechanism of action of GLP-1 agonists in neurons is also shown in Figure 1 . Exenatide, the first synthetic GLP-1 agonist, was recently studied for potential disease-modifying effects in a randomized, placebo-controlled clinical trial in patients with moderate PD, finding positive effects on motor severity (measured after overnight dopaminergic medication withdrawal) that were sustained 12 weeks beyond the period of exenatide exposure. 42 Given its positive clinical effects in the trial and preclinical data suggesting modulation of insulin signaling as its main mechanism of action, our a priori hypothesis was that exenatide-treated compared with placebo-treated participants would show changes in IRS-1 p-Tyr signaling proteins in neuronal-enriched EVs, suggesting activation of brain insulin signaling pathways. Our analysis used patient serum samples to identify changes in insulin signaling biomarkers in neuronalenriched EVs during multiple time points.
Key Points
Question How might neuronal-derived exosomes be used to explore the molecular mechanisms by which an experimental intervention exerts clinical effects on motor function? 
Outcomes
On the basis of previous literature, 35,36,39,41 our a priori hypothesis was that exenatide treatment would activate insulin signaling pathways detectable as a change in IRS-1 p-Tyr at the end of 48 weeks of treatment with exenatide. Additional exploratory outcomes were (1) differences between exenatide and placebo in other related IRS-1 signaling proteins and (2) downstream effectors of the Akt and MAPK pathways-the 2 pathways primarily involved in GLP-1 and insulin signaling. We further hypothesized that these changes would be associated with the positive motor effects seen in the clinical trial. Because of the limited amount of serum samples available, we were able to assess only a limited candidate group of biomarkers and selected Akt, extracellular signal-related kinase (Erk), total p38 (t-p38) MAPK, phospho p38 MAPK, c-Jun N-terminal kinase (JNK), GSK-3β, and mTOR.
Serum Sample Collection
Whole blood samples were collected in accordance with preprocessing guidelines for EV-based biomarker analysis. Samples from baseline, week 24, week 48, and week 60 were analyzed.
Isolation of EVs and Enrichment for Neuronal Origin
Investigators at the National Institute on Aging who performed EV isolation and protein quantifications were masked to exenatide and placebo treatment allocation. A detailed description of the methods and evidence for neuronal enrichment has been previously published. 47 A 2-step method of particle precipitation to increase EV concentration was followed by immune capture for neuronal surface antigen L1CAM to selectively isolate extracellular vesicles enriched for neuronal origin.
1,48
Quantification of EV Insulin Signaling Proteins All assays were conducted in duplicate, and the mean coefficients of variance were less than 10%. In all total protein assays, recombinant protein supplied by the manufacturer was used to calculate a standard curve and convert the electrochemiluminescence signal into concentrations. For phosphoproteins, the electrochemiluminescence signal was used for the analysis. All electrochemiluminescence values for total proteins were above the lowest limit of quantification and within the linear range of the curve. All samples from repeated visits of a given patient were included on the same plate to avoid within-subject variability caused by plate to plate variability. Plate to plate variability was assessed using an internal standard (EVs from a control patient; betweenplate coefficients of variance were <10%).
Statistical Analysis
Analyses were performed using SPSS statistical software, version 21.0 (IBM Corp). Biomarker values were natural log transformed to avoid skewness. To assess the effect of exenatide on a given biomarker, a linear mixed-effects model was used, with treatment groups (exenatide vs placebo), time, baseline biomarker, and EV concentration as fixed effects and participant identification treated as a random effect. The inclusion of EV concentration (determined by NanoSight) as a covariate enabled normalization for differential EV yield in different samples, as done previously.
37
To assess whether changes in biomarker levels were associated with the effect of treatment on disease progression, multiple linear regression of change in MDS-UPDRS Part 3 off-medication scores was fitted with change in biomarker levels, treatment group, EV concentration, and the interaction of biomarker change and treatment group as independent variables. Changes in MDS-UPDRS part 3 scores were defined as differences from baseline to 48 or 60 weeks. P < .05 was considered to be statistically significant. Statistical analysis was performed from May 1, 2017, to August 31, 2017.
Results

Patient Characteristics
Sixty patients (mean [SD] age, 59.9 [8.4] years; 43 [72%] male) participated in the study: 31 in the exenatide group and 29 in the placebo group. Data from 1 patient were excluded from the analysis because of extreme outlying values despite log transformation (eFigure 1 in the Supplement). Patient demographics and baseline characteristics were generally similar between the 2 groups (eTable 1 in the Supplement), although exenatide-treated participants were slightly older, had higher baseline MDS-UPDRS Part 3 scores, and had slightly lower levodopa equivalent dose than placebo-assigned participants. Comparison of biomarkers (log transformed) at baseline were similar between the 2 groups ( Figure 2 ). 
Association of Exenatide With Biomarker Changes
Exenatide-treated patients had an early and sustained increase in IRS-1 p-Tyr compared with placebo-assigned participants, resulting in a significant adjusted betweengroup difference at 24 weeks (0.22 absorbance unit [AU]; 95% CI, 0.04-0.39; P = .02), 48 weeks (0.27 AU; 95% CI, 0.09-0.44; P = .003), and 60 weeks (0.23 AU; 95% CI, 0.05-0.41; P = .01) ( Figure 3A) . By 48 weeks, there was also an (unexpected) increase in IRS-1 p-S616 of 0.096 AU (95% CI, −0.16 to 0.36) in the exenatide group compared with a decrease in the placebo group of −0.12 AU (95% CI, −0.37 to 0.15), resulting in a significant adjusted between-group difference of 0.22 AU (95% CI, 0.03-0.43; P = .047) ( Figure 3B ). A similar increase in IRS-1 p-S312 in the exenatide group at 48 weeks was observed, although the adjusted difference between the 2 groups (0.26 AU; 95% CI, −0.03 to 0.54; P = .07) did not reach significance ( Figure 3C ). These differences disappeared at 60 weeks.
We observed significant increases in t-Akt, p-Akt S473, and p-mTOR S2448 at 48 weeks in the exenatide group compared with the placebo group, resulting in adjusted between-group differences of 0.35 U/mL (95% CI, 0.16-0.53 U/mL; P < .001) for t-Akt, 0.18 U/mL (95% CI, 0.04-0.31 U/mL; P = .008) for p-Akt S473, and 0.22 AU (95% CI, 0.04-0.40 AU; P = .02) for p-mTOR ( Figure 4A , B, and D); p-Akt S473 was still significantly elevated in the exenatide group at 60 weeks (ie, 12 weeks after drug cessation; 0.15 AU; 95% CI, 0.01-0.28 AU; P = .03). No significant increases in t-mTOR (0.17 AU; 95% CI, −0.02 to 0.36; P = .09), t-GSK-3β (0.05 AU; 95% CI, −0.03 to 0.13 AU; P = .18), and p-GSK-3β S9 (0.08 AU; 95% CI, −0.04 to 0.19 AU; P = .20) were found at 48 weeks ( Figure 4C , E, and F). There were no significant changes in t-and p-p38 MAPK, Erk1/2, and JNK between the 2 groups at any time points ( Figure 5 ).
Association of Biomarkers With Clinical Scores
Consistent with the hypothesis that motor advantages seen with exenatide may relate (at least in part) to activation of the insulin, Akt, and mTOR cascades, we found that at 48 weeks changes in the levels of certain EV biomarkers significantly determined change in MDS-UPDRS Part 3 scores. These biomarkers were IRS-1 p-S616 (F 4,46 = 7.181, P < .001), t-mTOR (F 4,50 =5.34 3,P = .001), and p-mTOR S2448 (F 4,50 = 4.384, P = .04). Changes in biomarker levels and change in MDS-UPDRS Part 3 scores at 48 and 60 weeks are presented in the eTable 2 in the Supplement.
There were also corresponding significant interaction terms for group × change in biomarker for IRS-1 p-S616 (β = −11.15; 95% CI, −19.43 to −2.86; P = .009), t-mTOR (β = −9.22; 95% CI, −16.23 to −2.20; P = .01), and p-mTOR S2448 (β = −7.83; 95% CI, −15.62 to −0.04; P = .049). This finding indicates that at 48 weeks exenatide-related improvements in MDS-UPDRS Part 3 scores in the exenatide-treated group were significantly associated with changes in these biomarkers (eFigures 2 and 3 in the Supplement). There was no significant association between MDS-UPDRS part 3 scores and the levels of the other biomarkers tested.
In the clinical trial, clinical advantages in motor scores persisted at 60 weeks (ie, 12 weeks after drug cessation). At 60 weeks, the regression models assessing the associations between changes in EV biomarkers and change in MDS-UPDRS Part 3 scores were statistically significant for t-mTOR (F 4,47 =4. 924,P = .002), with a corresponding significant interaction term for t-mTOR (β = −10.05; 95% CI, −17.95 to −2.16; P = .01). Although this finding was nonsignificant, changes in p-Akt S473 were potentially associated with changes in motor scores (F 4,50 = 2.191, P = .08; interaction term β = −10.46; P = .047) (eFigures 4 and 5 in the Supplement). There was no significant association between MDS-UPDRS Part 3 scores and t-Akt, t-and p-GSK-3β, p38 MAPK, Erk 1/2, or JNK and no significant group × change in biomarker interactions.
Discussion
The current study demonstrates the potential use of EVs harvested from peripheral blood samples and enriched for neuronal origin as a source of biomarkers to gauge molecular responses to therapeutic interventions in clinical trials for Although there are some inconsistencies in the association between the clinical improvements and some of the upstream biomarker changes, these findings provide further support to our a priori hypothesis relating to one of the potential mechanisms through which treatment with exenatide may confer clinical benefits in PD. They also provide further support for the association between insulin resistance and PD pathogenesis. Although GLP-1 receptor stimulation can directly activate Akt, 38 our findings that the observed exenatideassociated changes in IRS-1 were accompanied by changes in Akt and mTOR suggest that modulation of insulin signaling at multiple levels may better account for the observed effects. Although exenatide was associated with increased IRS-1 p-Tyr in neurons as we hypothesized, we also found that exenatide was associated with increased IRS-1 p-S616 and IRS-1 p-S312, particularly between 24 and 48 weeks, possibly because of negative feedback via sustained mTORC1 activation (see eResults in the Supplement for detailed discussion). We found the changes in IRS-1 p-Tyr were also associated with increased t-Akt and p-Akt S473, and an association was observed between persistent motor benefits at 60 weeks and elevation of p-Akt S473. Our results are consistent with previous suggestions that pharmacologic upregulation of the Akt pathway may underlie the neuroprotective effects of many putative disease-modifying strategies 49 Although the data from this study support the notion that exenatide-associated effects on the insulin and Akt signaling pathway in neurons were associated with clinical benefit, whether these changes are ultimately associated with ; therefore, reversing this could lead to better dopaminergic transmission (and, therefore, a functional benefit). Conversely, reversal and restoration of dysfunctional neuronal insulin signaling in cultured cells and animals using GLP-1 agonists have been associated with reduction in cell death, aggregation of toxic oligomers, and inflammation, suggesting a disease-modifying effect that may also be reflected by functional improvements. 32, 33, 41, 76 Another possibility is that the clinical improvement and biomarker changes were produced in parallel through independent mechanisms of action of exenatide: GLP-1 stimulation is known to increase intracellular cyclic adenosine monophosphate, 77 which can inhibit serine phosphorylation of IRS-1 (thereby producing biomarker changes), and upregulates the expression and activity of tyrosine hydroxylase, 78 the rate-limiting enzyme in the synthesis of dopamine (thereby producing a clinical symptomatic effect). We deem this possibility as less likely given the associations between clinical and biomarker changes as well as the persistence of biomarker changes after the washout. Beyond these effects on insulin signaling, a further potential mechanism of action of exenatide that was not captured by the methods used in this study may relate to an anti-inflammatory effect of GLP-1 receptor stimulation on microglial cells and consequent reduction of conversion of astrocytes to the neurotoxic A1 subtype. 79 The methods for 
Limitations
Our approach to EV isolation has some limitations. It is widely recognized that no technique is perfect for EV isolation and removal of soluble content; however, combining 2 techniques (ie, particle precipitation and immune capture, as done here) is preferable to each one alone. 45 Moreover, selectively isolating neuronal-derived EVs relies on immunoprecipitation using antibodies against L1CAM, a cell surface marker highly (but not exclusively) expressed on neurons that has been accepted as a neuronal marker. Given that the insulin signaling, Akt, and mTOR pathways are not specific to neurons and the residual contamination of some nonneuronal EVs, it is not possible to assert that the effects of exenatide on EV biomarkers is solely attributable to neurons. Amelioration of insulin resistance in nonneuronal tissues may thus be a contributory factor to the reported results. Although this issue is of no concern when assaying proteins that are only neuronally expressed, further work to optimize the isolation of EVs of pure neuronal origin will further assist future assessments of drug actions in which both central and peripheral mechanisms may theoretically contribute to clinical effects.
Conclusions
We present, to our knowledge, the first biomarker evidence that peripherally administered exenatide may engage and normalize brain insulin signaling in association with activation of Akt and mTOR cascades in PD. Furthermore, exenatide-related changes in EV biomarkers were significantly associated with clinical improvements and could potentially be further used to assess target engagement and treatment response for this class and other classes of drugs. The use of neuronal originenriched EVs obtained from peripheral sources provides a simple, practical method for elucidating target engagement that should be further investigated in prospective clinical trials of putative disease-modifying interventions. Exenatide regulates substrate preferences through the p38γ MAPK pathway after ischaemia/ reperfusion injury in a rat heart. Heart Lung Circ. 
There was a significant interaction term for t-mTOR and p-mTOR S2448 indicating that exenatide induced improvements in UPDRS Part3 were in part modulated by / dependent on increases in t-mTOR and p-mTOR S2448. There were no significant differences between the two groups for t-Akt, p-Akt S273, t-GSK3B and p- 
There was a significant interaction term for p-Akt S273 and t-mTOR indicating that exenatide induced improvements in UPDRS Part3 at 60 weeks were in part modulated by /dependent on increases in p-Akt S273
and t-mTOR. There were no significant differences between the two groups for t-Akt, p-Akt S273, t-GSK3B and p-GSK3B S9 however the slopes indicate possible relationships between increases in t-Akt and p-mTOR S2448 and lower UPDRS Part 3 scores. (-1.00, -0.01), p=0.045) in the exenatide group with no significant associations in the placebo group.
Exenatide induces early and sustained phosphorylation of IRS-1 at tyrosine residues Our findings suggest that exenatide promoted tyrosine IRS-1 phosphorylation in neurons. However, unexpectedly, we found that exenatide was also associated with increased IRS-1p S616 and IRS-1p S312
particularly between 24 and 48 weeks. Interestingly, whereas elevated levels of IRS-p Tyr were still evident 12 weeks after cessation of exenatide, the increases in IRS1-p-S312 and IRS1-p-S616 had completely reverted by 60 weeks. Previous literature suggests that IRS-1 phosphorylated on residues S616 and S312 prevent binding However, one should bear in mind that the insulin signalling pathway is tightly regulated, with numerous negative feedback mechanisms. For example mTORC1, when activated, phosphorylates ribosomal protein S6 kinase beta-1 (S6K1), which in turn targets IRS-1 and promotes its serine phosphorylation at multiple sites 22, 49 and thus this negative feedback via mTORC1/S6K1 may account for the seemingly paradoxical findings in IRS-1 pS616 and IRS-1p S312. Furthermore certain phosphospecies of signalling molecules have a dual role (not 50 . It is therefore possible that IRS-1 pS616 and IRS-1p S312 may play a dual role potentially enhancing insulin signalling 51 , depending on the overall balance of influences on the cascade as a whole. IRS-1 phosphorylation on tyrosine residues allows the downstream activation of multiple effectors and the persisting elevation of IRS-1 pTyr seen at 60 weeks is intriguing however whether exenatide induces chronic beneficial effects on insulin signalling pathways is uncertain and longer term data is needed.
